HiFiBiO Therapeutics, a Cambridge, MA-based biotherapeutics company, raised $37.5m in Series B funding.
The round was led by Sequoia China and LYFE Capital with participation from VI Ventures, Nest.Bio Ventures, Legend Star Capital and Proxima Ventures.
Led by President and CEO Liang Schweizer, PhD., HiFiBiO Therapeutics is a multinational biotherapeutics company mobilizing the human immune system to combat disease. The company integrates deep-rooted biological expertise with single-cell profiling technologies to discover and advance a pipeline of antibody drugs to treat cancer and autoimmune disorders.
The team also includes Jeff He, Chief Operating Officer, Colin Brenan, PhD, Chief Commercial Officer, Fred Dom, Chief Financial Officer and over 50 full-time employees operating out of three facilities in the USA, France and China. Both the laboratories in Cambridge, Mass. and Hangzhou, China are located within the Nest.Bio Ventures incubator facilities.
The company continues to establish multiple strategic partnerships with pharmaceutical and biotechnology companies to drive an innovative pipeline of antibody drugs that leverage its proprietary single-B-cell functional antibody discovery CelliGOTM platform.